Tag archive for ‘A.P. Pharma Inc.’
Initiating Coverage of A.P. Pharma with a Buy (APPA, $0.42)
I have just published a report initiating coverage on A.P. Pharma (APPA, $0.42) in which I recommend purchase; my 2015 price target is $5.00+. The recommendation is keyed to the projected approval of APF530 for the treatment of chemotherapy induced nausea and vomiting in early 2013 and launch in the US in mid-2013. Most newly […]
A.P. Pharma: Initiating Coverage with a Buy (APPA.OB, $0.42)
Key Investment Conclusions In this report, I have made projections for sales, earnings and cash flow for A.P. Pharma (APPA.OB) through 2016. The underlying assumptions and calculations are explained within this report. However, let’s start with the conclusions. My base investment case is that A.P. Pharma will gain approval for its first commercial product APF530 in […]